KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients with Essential Hypertension: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomised study.

Hongjie Chi, Xin Zhang, Shumei Ma, Gang Pan, Xiaojuan Lian, Yuanyuan Chen, Yan Chen, Hao Tang, Zichen Liu, Peng Mi, Xiangmin Lin

J Hum Hypertens 39(7) 500-508

PMID40527906
PMCIDPMC12343297
DOI10.1038/s41371-025-01035-3
发表日期2025-06-17
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:森林图/亚组分析图;Fig. 5:AI 判定为 other;另有 1 张未列出。
摘要

摘要

This multicenter, double-blind, parallel-group, randomised controlled phase III study evaluated the efficacy and safety of the Allisartan Isoproxil 240 mg /Amlodipine 5 mg (ALI/AML) combination compared with ALI 240 mg monotherapy in patients with mild-to-moderate essential hypertension. Patients aged 18 to 70 years with mean sitting systolic blood pressure (msSBP) between 140 and <180 mmHg and mean sitting diastolic blood pressure (msDBP) between 90 and <110 mmHg were randomised 1:1 to receive ALI/AML or ALI once-daily for 12 weeks after a 4-week treatment with ALI, followed by an open-label extension period with ALI/AML up to week 52. A total of 199 patients were randomised (ALI/AML: n = 99, ALI: n = 100) with 169 completing the study. Baseline characteristics were comparable between groups. After 12 weeks of randomisation, the reduction in msSBP (primary endpoint) was significantly greater in the ALI/AML group vs the ALI group (-18.3 vs. -9.3 mmHg, p < 0.001). Reductions in msDBP (-6.0 vs. -1.9 mmHg, p < 0.001) and 24-hour mean ambulatory systolic/diastolic blood pressure (-19.9/-10.1 vs. -6.9/-4.2 mmHg) were more pronounced in the ALI/AML group. Additionally, a greater proportion of patients achieved the BP response and target office BP in the ALI/AML group compared to the ALI group (53.6% vs. 25.5%, p < 0.001; 40.2% vs. 20.4%, p=0.0026). AML/ALI combination was generally safe and well tolerated, with sustained efficacy up to 52 weeks. The study concluded that ALI/AML offers a convenient, single-pill option for effective BP reduction in hypertensive patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patient disposition.
非 KM Figure
Fig. 2Fig. 2 Comparison of change from baseline to Week 12 in msSBP and msDBP between ALI/AML (240/5 mg) and ALI (240 mg) groups(MMRM). LSM indicates least square mean.
非 KM Figure
Fig. 3Fig. 3. Proportion of responders and target BP rates in the double-blind period (Logistic Regression). a Proportion of responders (msSBP/msDBP<140/90 mmHg, or a reduction in msSBP >20 mmHg and/or mean msDBP >10 mmHg). b Target BP rates (msSBP/msDBP<140/90 mmHg).
非 KM Figure
Fig. 4Fig. 4 Changes in msSBP from baseline to Week 12 in different subgroups between ALI/AML (240/5 mg) and ALI (240 mg) groups. LSM indicates least square mean(MMRM).
非 KM Figure
Fig. 5Fig. 5 LSM change from baseline to Week 12 in ambulatory blood pressure between ALI/AML (240/5 mg) and ALI (240 mg) groups (ANCOVA). LSM indicates least square mean(MMRM).
非 KM Figure
Fig. 6Fig. 6. Postdosing hourly mean ambulatory SBP and DBP at Week 12 with Allisartan Isoproxil/Amlodipine vs. Allisartan Isoproxil groups. a Mean ambulatory SBP (n = 8). b Mean ambulatory DBP (n = 9).
非 KM Figure